This article is more than 5 years old. Information may no longer be current.
Researcher to lead expansion of Perlmutter Cancer Center’s leukemia programs
Click Here to Manage Email Alerts
NYU Langone Health selected Raoul Tibes, MD, PhD, to expand the clinical and investigative leukemia programs at its Perlmutter Cancer Center.
Tibes previously served as assistant professor of medicine at clinical consultant to Mayo Clinic in Arizona.
His research has focused on development of therapies for acute lymphoblastic leukemia, acute myeloid leukemia and myelodysplastic syndrome. He also has strived to identify mechanisms of resistance to therapies for these diseases.
“I am honored to join Perlmutter Cancer Center and to be asked to lead the clinical and translational leukemia program,” Tibes, who also will serve as associate professor of hematology and medical oncology at NYU School of Medicine, said in a press release. “Leukemia is a disease that affects tens of thousands of Americans every year. The research we conduct, and its translation into clinical practice, will ensure patients have access to the latest treatment options available to them.”
In his new role, Tibes will develop investigator-initiated trials and specific biomarkers for hematologic malignancies. He will work closely with Samer-Al Homsi, MD, who recently was appointed the director of bone marrow transplantation at NYU Langone Health.
“Dr. Tibes has a unique expertise and perspective, as both a clinician and a researcher, to lead the clinical application of genomic discoveries and advances in targeted therapies for blood cancer,” Benjamin G. Neel, MD, PhD, director of Perlmutter Cancer Center, said in a press release. “Under his leadership, we will improve the care and quality of life for patients by moving preclinical results and novel therapeutic combinations more rapidly into the clinic.”